Oncolytics Biotech is pleased to announce the submission of a Type C meeting request to the FDA. This meeting aims to discuss the company’s planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer. “A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment. We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer. Our position is strengthened by encouraging data from two randomized studies (BRACELET-1 and IND-213) and the AWARE-1 study, paving the way for the next phase of pelareorep’s development and its registration. Ongoing discussions with our clinical collaborators and partners have helped us to prepare a robust, compelling briefing document,” said Dr. Matt Coffey, President and CEO of Oncolytics. “We eagerly anticipate our discussion with the FDA to align on the design and objectives of the registrational trial for pelareorep in metastatic breast cancer, a critical step towards bringing this innovative treatment to patients. Having a well-defined plan for the registrational track study will also help advance our strategic partnering discussions. We hope to meet with the agency in Q2 2024 and look forward to a productive dialogue. With anticipated overall survival data from the BRACELET-1 study and productive discussions with the FDA, 2024 is poised to be a transformative year for Oncolytics and our stakeholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics initiated with an Outperform at Raymond James
- Oncolytics Biotech Showcases at Oncology Event
- Oncolytics Biotech Showcases at Oncology Conference
- Oncolytics Biotech Shows Promising Cancer Drug Progress
- Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights